Leaflet: information for the user
Amlodipino/Valsartán Aurovitas10 mg/160 mg film-coated tablets EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What isAmlodipino/Valsartán Aurovitasand what it is used for
2. What you need to know before you start takingAmlodipino/Valsartán Aurovitas
3. How to takeAmlodipino/Valsartán Aurovitas
4. Possible side effects
5. Storage ofAmlodipino/Valsartán Aurovitas
6. Contents of the pack and additional information
Amlodipino/Valsartán Aurovitas contains two substances called amlodipino and valsartán. Both substances help control high blood pressure.
This means that both substances help prevent blood vessel constriction. As a result, blood vessels relax and blood pressure decreases.
Amlodipino/valsartán is used to treat high blood pressure in adults whose blood pressure is not adequately controlled with amlodipino or valsartán alone.
Do not take Amlodipino/Valsartán Aurovitas:
Do not take Amlodipino/Valsartán Aurovitas and inform your doctor if you are affected by any of the above cases.
Warnings and precautions
Consult your doctor before taking Amlodipino/Valsartán Aurovitas:
Your doctor may check your kidney function, blood pressure, and electrolyte levels (such as potassium) at regular intervals.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking amlodipine/valsartan. Your doctor will decide whether to continue treatment. Do not stop taking amlodipine/valsartan on your own.
See also the information under the heading “Do not take Amlodipino/Valsartán Aurovitas”.
Inform your doctor before taking Amlodipino/Valsartán Aurovitas if you are affected by any of the cases mentioned.
Children and adolescents
Amlodipino/Valsartán Aurovitas is not recommended for use in children or adolescents (under 18 years old).
Taking Amlodipino/Valsartán Aurovitas with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication. Your doctor may need to adjust your dose and/or take other precautions.
In some cases, you may need to stop taking one of the medications. This applies especially to the medications listed below:
Taking Amlodipino/Valsartán Aurovitas with food and drinks
People taking amlodipine/valsartan should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice may cause an increase in the blood levels of the active ingredient amlodipine, which may lead to unpredictable reductions in blood pressure.
Pregnancy, breastfeeding, and fertility
Pregnancy
Inform your doctor if you are pregnant, if you suspect you may be pregnant, or if you plan to become pregnant.If you are pregnant, your doctor will usually advise you to stop taking amlodipine/valsartan before becoming pregnant or as soon as you become pregnant, and recommend taking another antihypertensive medication instead. Amlodipine/valsartan is not recommended for use during the first 3 months of pregnancy and should not be administered after the third month of pregnancy as it may cause severe harm to your baby when administered from that time.
Breastfeeding
Inform your doctor if you plan to start or are breastfeeding.
Amlodipine has been shown to pass into breast milk in small amounts. Amlodipine/valsartan is not recommended for use during this period. Your doctor may decide to administer a more suitable treatment if you want to breastfeed, especially in newborns or premature babies.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
This medication may cause dizziness, which may affect your ability to concentrate. Therefore, if you are unsure how this medication will affect you, do not drive, operate machinery, or perform other activities that require concentration.
Amlodipino /Valsartán Aurovitas contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again. This will help you obtain the best results and reduce the risk of adverse effects.
The usual dose of amlodipino/valsartán is one tablet per day.
Your doctor may suggest a higher or lower dose depending on your response to treatment.
Do not exceed the prescribed dose.
Amlodipino/Valsartán Aurovitas and Older Adults (65 years or older)
Your doctor should exercise caution when increasing the dose.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
If You Take More Amlodipino/Valsartán Aurovitas Than You Should
Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that may develop within 24-48 hours after ingestion.
If you have taken too many amlodipino/valsartán tablets, or if someone else has taken your tablets, consult a doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If You Forget to Take Amlodipino/Valsartán Aurovitas
If you forget to take this medication, take it as soon as you remember. Then take the next dose at the usual time. However, if it is almost time for the next dose, do not take the missed dose. Do not take a double dose to make up for the missed doses.
If You Interrupt Treatment with Amlodipino/Valsartán Aurovitas
Stopping your treatment with amlodipino/valsartán may cause your condition to worsen. Do not stop taking your medication unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Some side effects can be serious and require immediate medical attention:
A few patients have experienced these serious side effects(which can affect up to 1 in 1,000 patients).Notify your doctor immediately if you notice any of the following:
allergic reaction with symptoms such as skin rash, itching, swelling of the face, lips, or tongue, difficulty breathing, low blood pressure (dizziness, fainting).
Other possible side effects of amlodipine/valsartan:
Frequent (can affect up to 1 in 10 patients):flu; stuffy nose, sore throat, and discomfort when swallowing; headache; swelling in the arms, hands, legs, ankles, or feet; fatigue; asthenia (weakness); flushing and sensation of heat in the face and/or neck.
Infrequent (can affect up to 1 in 100 patients):dizziness; nausea and abdominal pain; dry mouth; somnolence, tingling, or numbness in the hands or feet; vertigo, rapid heart rate including palpitations; dizziness upon standing; cough; diarrhea; constipation; skin rash, redness of the skin; joint inflammation, back pain; joint pain.
Rare (can affect up to 1 in 1,000 patients):sensation of anxiety; ringing in the ears (tinnitus); fainting; increased urine production or sensation of urgency to urinate; inability to achieve or maintain an erection; sensation of heaviness; low blood pressure with symptoms such as dizziness, fainting; excessive sweating; skin rash all over the body, itching, muscle spasms.
Notify your doctor if you are severely affected by any of the cases mentioned.
Side effects reported with amlodipine or valsartan alone and not observed with Amlodipino/Valsartán Aurovitas or observed with a higher frequency than with Amlodipino/Valsartán Aurovitas:
Amlodipine
Consult your doctor immediately if you experience any of the following severe side effects, which are very rare, after taking this medicine:
The following side effects have been reported. If any of these cause problems or last more than a week, consult your doctor.
Frequent (can affect up to 1 in 10 patients):dizziness, somnolence; palpitations (feeling the heartbeat); hot flashes, swelling of the ankles (edema); abdominal pain, discomfort (nausea).
Infrequent (can affect up to 1 in 100 patients):mood changes, anxiety, depression, somnolence, tremor, alterations in taste, fainting; visual disturbances, visual deterioration, ringing in the ears; decreased blood pressure; nasal congestion or secretion caused by inflammation of the nasal mucosa (rhinitis); indigestion, vomiting (discomfort); hair loss, increased sweating, itching skin, skin discoloration; urinary disorders, increased need to urinate at night, increased frequency of urination; inability to achieve an erection, discomfort or breast enlargement in men, pain, discomfort, muscle pain, muscle cramps; weight gain or loss.
Rare (can affect up to 1 in 1,000 patients):confusion.
Very rare (can affect up to 1 in 10,000 patients):decreased white blood cell count, decreased platelet count that can cause easy bleeding or unusual bruises (damage to red blood cells); high blood sugar (hyperglycemia); inflammation of the gums, abdominal swelling (gastritis); abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), increased liver enzymes that can affect some medical tests; muscle tension; inflammation of blood vessels often with skin eruptions, light sensitivity; disorders combining stiffness, tremor, and/or movement disorders.
Valsartan
Very rare (can affect up to 1 in 10,000 people):Intestinal angioedema: swelling in the intestine with symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Frequency not known (cannot be estimated from available data):decreased red blood cell count, fever, sore throat, or ulcers in the mouth due to infection; spontaneous bleeding or skin hematomas; increased potassium in the blood; abnormal liver function test results; decreased kidney function and severely decreased kidney function; swelling, mainly of the face and throat; muscle pain; skin rash, red purpura spots; fever; itching; allergic reaction, blistering skin disease (sign of a disease called dermatitis bullosa).
Notify your doctor immediately if you experience any of the cases mentioned.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and in the blister pack after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Amlodipino/Valsartán Aurovitas
Each tablet contains 10 mg of amlodipine (as amlodipine besilate) and 160 mg of valsartan.
Tablet core:microcrystalline cellulose(grade - 101),anhydrous colloidal silica, sodium carboxymethylcellulose (type A) (from potato), povidone(K-30),pregelatinized cornstarch, magnesium stearate.
Tablet coating:hypromellose 2910 (E464), titanium dioxide (E 171), talc, macrogol, yellow iron oxide (E 172), red iron oxide (E 172).
Appearance of the product and content of the container
Ovaloid, biconvex, bisected edge, light yellow, tablet with a«J»engraving on one face and«38»engraving on the other face.
Amlodipino/Valsartán Aurovitas coated tablets are available in blisters of polyamide/aluminum/PVC-aluminum foil containing 28 tablets.
Marketing authorization holder and responsible manufacturer:
Marketing authorization holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos 16-D
28036 – Madrid
Responsible manufacturer:
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
Last review date of this leaflet:February 2025
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.